Minerva Neurosciences, Inc (NERV) Given Consensus Rating of “Hold” by Brokerages

Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) have received a consensus rating of “Hold” from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $16.00.

A number of equities analysts recently commented on the stock. BidaskClub raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th.

Minerva Neurosciences (NASDAQ:NERV) opened at $6.60 on Monday. Minerva Neurosciences has a 1 year low of $4.80 and a 1 year high of $11.15. The company has a market cap of $270.90, a PE ratio of -5.89 and a beta of 1.53.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter. During the same period last year, the company earned ($0.24) EPS. equities analysts predict that Minerva Neurosciences will post -1.28 EPS for the current fiscal year.

In other Minerva Neurosciences news, CFO Geoff Race sold 5,829 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $5.79, for a total transaction of $33,749.91. Following the sale, the chief financial officer now directly owns 197,698 shares in the company, valued at $1,144,671.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have sold 12,590 shares of company stock worth $73,073. 21.60% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in NERV. FMR LLC grew its stake in Minerva Neurosciences by 13.7% during the second quarter. FMR LLC now owns 5,660,794 shares of the biopharmaceutical company’s stock worth $50,098,000 after buying an additional 680,000 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in Minerva Neurosciences during the third quarter worth about $2,835,000. EcoR1 Capital LLC acquired a new stake in Minerva Neurosciences during the second quarter worth about $1,981,000. DAFNA Capital Management LLC grew its stake in Minerva Neurosciences by 172.7% during the second quarter. DAFNA Capital Management LLC now owns 276,317 shares of the biopharmaceutical company’s stock worth $2,445,000 after buying an additional 175,000 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its stake in Minerva Neurosciences by 31.9% during the third quarter. Sphera Funds Management LTD. now owns 625,000 shares of the biopharmaceutical company’s stock worth $4,750,000 after buying an additional 151,231 shares in the last quarter. Hedge funds and other institutional investors own 73.68% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/29/minerva-neurosciences-inc-nerv-given-consensus-rating-of-hold-by-brokerages.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply